Sept 15 - Britain's FTSE 100 index is seen opening six points higher at 6,032 on Tuesday, according to financial bookmakers. * ASTRAZENECA: AstraZeneca's COVID-19 vaccine trial remains on hold in the United States pending a U.S. investigation into a serious side effect in Britain even as other trials of the vaccine resume, sources familiar with the details told Reuters. * G4S: Britain's G4S said on Monday it had rejected a 2.95 billion pound offer from Canadian security firm GardaWorld, saying it was "highly opportunistic". * GOLD: Gold prices rose on Tuesday as the dollar remained subdued, with investors turning their focus to a U.S. Federal Reserve monetary policy meeting, seeking details of its plans on inflation targeting. * OIL: Oil prices slipped on Tuesday as worries over slow recovery in global fuel demand were reinforced by warnings by major oil producers, but short-covering ahead of a meeting later this week of OPEC and its allies, known as OPEC+, limited losses. * The UK blue-chip index shed 0.1% on Monday, as the prospect of waning demand weighed on heavyweight energy stocks, while security firm G4S propped up the midcap index after it rejected a takeover from Canadia's GardaWorld. * UK CORPORATE DIARY: Eve Sleep Plc HY results Ocado Plc Q3 trading statement Marshalls Plc HY results Polypipe Group Plc HY results Jtc Plc HY results * For more on the factors affecting European stocks, please click on: TODAY'S UK PAPERS > Financial Times > Other business headlines (Reporting by Samantha Machado in Bengaluru)
Our Standards: The Thomson Reuters Trust Principles.